# Dexlansoprazole

## Dexilant delay-release 60mg

| TAH Drug Code      | [ODEXI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ODEXI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of erosive esophagitis (EE) in patients aged 12 and above for up to 8 weeks. Maintenance of healed erosive esophagitis in patients aged 12 and above who have already healed from EE; in adults for up to 6 months, and in patients aged 12-17 for up to 16 weeks. Symptomatic treatment of non-erosive gastroesophageal reflux disease (GERD) in patients aged 12 and above for a duration of 4 weeks.                                                                                                                                                                                                                                                                                                   |
| Dosing             | Erosive esophagitis, Healing of all grades Age > 12 years-old, 60 mg orally once daily for up to 8 weeks. Erosive esophagitis, Maintenance of healing - Heartburn 30 mg orally once daily for up to 6 months. Gastroesophageal reflux disease, nonerosive 30 mg orally once daily for 4 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | Known hypersensitivity (eg, anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, urticaria) to dexlansoprazole or any component of the formulation; concomitant use with products that contain rilpivirine.                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Adverse Effects    | Common: Abdominal pain (3.5-5%), Diarrhea (4.7-5.1%), Flatulence (1.4-2.6%), Nausea (2.8-3.3%), Vomiting (1.4-2.2%), Nasopharyngitis (Pediatric, 5% or greater), Pain, Oropharyngeal (Pediatric, 5% or greater), Upper respiratory infection (1.7-2.9%). Serious: Cutaneous lupus erythematosus, Generalized exanthematous pustulosis, acute, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Cobalamin deficiency (Rare), Hypomagnesemia, Clostridium difficile diarrhea, Fundic gland polyposis of stomach, Anaphylaxis, Drug reaction with eosinophilia and systemic symptoms, Hypersensitivity reaction (<2%), Systemic lupus erythematosus, Fracture of bone (<2%), Tubulointerstitial nephritis, acute. |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| More Info          | [UpToDate](https://www.uptodate.com/contents/dexlansoprazole-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

